Trial Profile
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 May 2019
Price :
$35
*
At a glance
- Drugs Eltrekibart (Primary)
- Indications Psoriasis; Skin disorders
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 01 May 2019 Status changed from active, no longer recruiting to completed.
- 29 Apr 2019 Planned End Date changed from 2 Apr 2019 to 1 Apr 2019.
- 02 Jan 2019 Status changed from recruiting to active, no longer recruiting.